Drugs / PBMCs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06734520 | Oct 2024 → Jul 2029 expected | beta-thalassemia major | Guangzhou Women and Children's Medical Center | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 27
| Date | Issuer | Release |
|---|---|---|
| 2026-08-06 | CancerVax Corporation | Results CancerVax Achieves Major Milestone in Activating Human Killer T-Cells Against Cancer cancervax.com ↗
In-vitro studies confirmed that the Company’s revolutionary therapy successfully disguised liver cancer cells as virally infected cells and activated pre-existing human antiviral Killer T-cells |
| 2025-11-10 | HCW Biologics | Results HCW Biologics Shares the Latest Data for its Second-Generation Immune Checkpoint Inhibitor Presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer hcwbiologics.com ↗
HCW11-040 expands and activates human peripheral blood lymphocytes (PBMCs) and memory T cells significantly better than pembrolizumab alone. |
| 2025-04-28 | Clasp Therapeutics, Inc. | Results Clasp Therapeutics Presents Nonclinical Data Supporting GUARDIAN-101 Phase 1 Clinical Study of CLSP-1025 at the 2025 AACR Annual Meeting clasptx.com ↗
CLSP-1025 did not cause target independent T cell activation or cytokine release in peripheral blood mononuclear cells (PBMCs) or show any activity towards normal healthy tissue. |
| 2025-04-25 | iOmx Therapeutics AG | Results Pharmacodynamic biomarker modulation by OMX-0407, a novel, spectrum-selective kinase inhibitor for the treatment of angiosarcoma and renal cell carcinoma iomx.com ↗
A flow-cytometry-based “phosFlow” assay confirmed OMX-0407 effects on the phosphorylation of SFKs in PBMCs at doses of 60 mg and above. |
| 2025-04-04 | Arvinas Inc. | Results Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation arvinas.com ↗
Inhibition of Rab10 phosphorylation in PBMCs and reduction of bis(monoacylglycerol)phosphate (BMP) in urine following single doses of ARV-102, signifying downstream LRRK2 pathway engagement. |
| 2024-12-17 | Aposcience AG | Results Paper on content analysis of APOSEC recently published aposcience.at ↗
Subsequently, in vitro assays showed that the exosome and protein fractions of irradiated and non-irradiated PBMC secretome were the major biological components that enhanced cell mobility; conversely, secreted lipids and microparticles had no effects. |
| 2024-11-18 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results AASLD 2024 | HANSOH PHARMA RELEASES FOUR RESEARCH FINDINGS ON TENOFOVIR AMIBUFENAMIDE hspharm.com ↗
The study found significantly higher baseline levels of HBVDNA, HBV RNA, and HBsAg in the HBeAg-positive CHB group compared to the HBeAg-negative group. |
| 2024-05-14 | Celularity Incorporated | Results Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy celularity.com ↗
This translated into improved and prolonged in vivo efficacy and persistence compared with healthy, adult PBMC-derived CAR-T. |
| 2023-11-03 | Immunitas Therapeutics | Results Immunitas Therapeutics Presents New Data for TLR9 Agonist Conjugate at the Society for Immunotherapy of Cancer 2023 Annual Meeting immunitastx.com ↗
Studies in human peripheral blood mononuclear cells (PBMCs) has demonstrated that treatment with the anti CLEC2D-TLR9 agonist ISAC did not trigger release of inflammatory cytokines, providing a preliminary indication of safety. |
| 2023-04-18 | invIOs GmbH | Results Press release: invIOs presents promising new clinical data in solid tumors from autologous cell therapy APN401 at AACR Annual Meeting 2023 invios.com ↗
APN401, a novel cancer therapy using Cbl-b silenced autologous PBMCs, induced stable disease in two patients with advanced solid tumors |
| 2022-11-11 | Antengene Corporation | Results Antengene Presents Promising Results from Four Preclinical Studies at the 2022 Society for Immunotherapy of Cancer Annual Meeting antengene.com ↗
Through these studies, results showed that ATG-018 inhibited the expression of a set of chemokine genes (CCL2, CCL3/1 and CCL4) and that they could be detected in unmanipulated blood samples. |
| 2022-10-26 | Equillium | Results Equillium Announces Presentation of Data Demonstrating Biological Importance of Multi-Cytokine Inhibitors EQ101 and EQ102 at the La Jolla Immunology Conference equilliumbio.com ↗
Treatment of PBMCs with EQ101 or EQ102 resulted in an approximate 50% decrease in proliferation of CD4 T cell subsets, and an approximate 40% decrease of CD8 subsets. |
| 2022-09-01 | TolerogenixX GmbH | Results TolerogenixX Publishes Three-Year Follow-Up Data from Phase I Trial of Immune Tolerance-Inducing MIC-Lx Cell Therapy tolerogenixx.com ↗
The results published ahead of print in the Journal of the American Society of Nephrology (doi: 10.1681/ASN.2022020210) indicate that donor-specific immunosuppression after MIC infusion is long-lasting and associated with a striking increase in regulatory B lymphocytes. |
| 2021-05-11 | Orchard Therapeutics | Results Orchard Therapeutics Announces New England Journal of Medicine Publication of HSC Gene Therapy Data for ADA-SCID orchard-tx.com ↗
VCN continued to increase in peripheral blood mononuclear cells (PBMCs) up to two years in all study patients and was sustained up to three years in UK study patients. |
| 2021-05-03 | Mendus | Results Immunicum AB Presents Preclinical Data for Ilixadencel and DCP-001 at the 18th Cancer Immunotherapy Annual Meeting mendus.com ↗
The preclinical evaluation of DCP-001 mixed with the host immune cells, called peripheral blood mononuclear cells (PBMCs), shows the induction of the production of various pro-inflammatory cytokines and chemokines by these PBMCs. |
| 2021-01-26 | Merck Sharp & Dohme LLC | Results Merck Presents Interim Findings from Phase 2a Clinical Trial Evaluating Investigational Once-Monthly Oral Islatravir for the Prevention of HIV-1 Infection at HIVR4P 2021 merck.com ↗
Interim PK analysis of islatravir triphosphate (the active form of islatravir) concentrations in peripheral blood mononuclear cells (PBMCs) showed that the trough concentrations (the lowest level between doses) following either 60 mg or 120 mg monthly doses remained above the pre-specified PK threshold for HIV-1 prophylaxis of 0.05 pmol/10 6 PBMCs. |
| 2020-11-09 | Celldex Therapeutics | Results Celldex Presents Data from Oncology Portfolio at SITC 2020 celldex.com ↗
Pre-treatment of patients with CDX-301 greatly increased the number of circulating dendritic cells prior to CDX-1140 administration and peripheral blood mononuclear cells (PBMCs) isolated from CDX-301 pretreated patients were more responsive to CDX-1140 than PBMCs from non-pretreated patients. |
| 2020-04-22 | Alkermes, Inc. | Results Alkermes Announces Publication of Preclinical Data for ALKS 4230 in the Journal for ImmunoTherapy of Cancer alkermes.com ↗
ALKS 4230 treatment of peripheral blood mononuclear cells (PBMCs) from patients with melanoma or renal cell carcinoma resulted in the selective expansion of CD8+ T cells and NK cells with negligible effects on Treg expansion. |
| 2019-07-23 | Gilead Sciences | Results Gilead Presents New Findings on Profile of Descovy® for Potential Use as HIV Pre-exposure Prophylaxis Compared With Truvada® gilead.com ↗
At Week 4, levels of TFV-DP in PBMCs were 6.3-fold higher with Descovy compared with Truvada, resulting in 98 percent of participants receiving Descovy had drug levels above the EC90 compared with 68 percent of participants taking Truvada. |
| 2018-12-06 | GT Biopharma, Inc. | Results GT Biopharma Presents Positive Preclinical Data of Tri-specific NK Cell Engager (TriKE) at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition gtbiopharma.com ↗
Treatment of peripheral blood mononuclear cells (PBMCs) with the CLEC12A TriKE drives a significant increase in NK cell specific proliferation over 7 days as measured by Cell Trace dilution compared to treatment with a CLEC12A scFv or IL-15 alone (69.7 ± 6.7% vs 11.9 ± 2.5% vs 38.4 ± 7.3%). |
| 2017-05-02 | Abivax S.A. | Results First ever evidence of treatment-induced reduction in HIV reservoirs abivax.com ↗
ABIVAX announced today that the company’s lead therapeutic candidate ABX464 demonstrated the first reduction in HIV reservoirs ever observed in chronically infected HIV patients as measured by total HIV DNA detected in peripheral blood mononuclear cells (PBMCs). |
| 2016-12-05 | CureVac | Results Study with CureVac’s RNAdjuvant® Technology Published in Cancer Immunology, Immunotherapy, Demonstrates Equal responsiveness of blood cells from Both Hepatocellular Carcinoma (HCC) Patients and Healthy Subjects to the RNA-based adjuvant curevac.com ↗
The study examined the effects of CureVac’s RNAdjuvant® technology on PBMCs obtained from eight healthy volunteers and 17 HCC patients, using a multiparametric approach to analyze network dynamics of early immune responses. |
| 2016-12-05 | Omeros Corporation | Results Omeros’ Proprietary Orphan GPCR Program Delivers New Target and Approach in Cancer Immunotherapy omeros.com ↗
Data from GPR174 inhibition in mouse PBMCs are consistent with the human PBMC findings. |
| 2016-03-07 | VBI Vaccines Inc. | Results VBI Presents New Data Supporting its Glioblastoma Immunotherapy Program at the Keystone Symposia Cancer Vaccines Conference vbivaccines.com ↗
Ex vivo studies demonstrated the vaccine candidate’s ability to induce desired anti-tumor immunity in peripheral blood mononuclear cells (“PBMCs”) obtained from healthy subjects and patients with GBM. |
| 2015-11-20 | VBI Vaccines Inc. | Results VBI Presents Update and New Data Supporting its Glioblastoma Immunotherapy Program at the ESMO Symposium on Immuno-Oncology vbivaccines.com ↗
Ex vivo studies demonstrate the vaccine candidate’s ability to induce desired anti-tumor immunity in peripheral blood mononuclear cells (“PBMCs”) harvested from healthy subjects and patients with GBM; |
| 2015-03-31 | Aposcience AG | Results APOSEC attenuates secondary damage following spinal cord injury aposcience.at ↗
The secretome of apoptotic human peripheral blood mononuclear cells attenuates secondary damage following spinal cord injury in rats |
| 2007-04-19 | Debiopharm International SA | Results Clinical update – Debio025 cyclophilin inhibitor for the treatment of HCV – A unique viral kinetics debiopharm.com ↗
Other data from the same study showed that during treatment, Cyp-B levels decreased significantly in peripheral blood mononuclear cells (PBMCs) after treatment with Debio025. |
All press releases naming this drug 28 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PBMCs | “the peripheral blood mononuclear cells (PBMCs) that contain a certain numbers of CD34+ stem cells and CD3+ lymphocytes will be extracted by blood cell separators” NCT06734520 ↗ |
| Known as | peripheral blood mononuclear cells | “the peripheral blood mononuclear cells (PBMCs) that contain a certain numbers of CD34+ stem cells and CD3+ lymphocytes will be extracted by blood cell separators” NCT06734520 ↗ |
| Route | Intravenous | “Pediatric patients will be infused with the PBMCs intravenously at day 0.” NCT06734520 ↗ |